Skip to main content
OpenTrials
Completed

NCT Number: NCT07729189

Prophylactic Use of Timolol Maleate to Prevent Intraocular Pressure Elevation After Nd:YAG Laser Posterior Capsulotomy

This randomized controlled trial evaluated whether a single drop of 0.5% timolol maleate, administered before neodymium-doped yttrium aluminium garnet (Nd:YAG) laser posterior capsulotomy, reduced the rise in intraocular pressure compared with standard care alone. The study included adults aged 18-65 years who had developed posterior capsular opacification at least 3 months after cataract surgery and were scheduled to undergo Nd:YAG laser posterior capsulotomy. Participants were randomly assigned to receive either prophylactic topical timolol maleate or standard care without prophylactic timolol. Intraocular pressure was measured before the laser procedure and again 1 hour after the procedure by an ophthalmologist who was unaware of the assigned treatment. The study was based on the hypothesis that mean intraocular pressure 1 hour after posterior capsulotomy would be lower among participants who received prophylactic timolol maleate than among those who received standard care alone.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CMH Institute of Medical Sciences

Multan, Punjab Province, 66000, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18-65 years
  • Male or female participants
  • Diagnosed with posterior capsule opacification after cataract surgery
  • Posterior capsule opacification present for at least 3 months
  • Scheduled to undergo Nd:YAG laser posterior capsulotomy

Exclusion criteria

  • History or documented diagnosis of glaucoma
  • Baseline intraocular pressure greater than 21 mmHg before the procedure

Treatment and study plan

timolol maleate

Drug

One drop of 0.5% timolol maleate ophthalmic solution was administered topically immediately before Nd:YAG laser posterior capsulotomy.

No intervention

Drug

No prophylactic intraocular pressure-lowering medication was administered before Nd:YAG laser posterior capsulotomy.

Primary outcomes

  1. Mean Intraocular Pressure 1 Hour After Nd:YAG Laser Posterior Capsulotomy

    Time frame: 1 hour after Nd:YAG laser posterior capsulotomy

    Intraocular pressure was measured in millimetres of mercury using a Canon non-contact tonometer. The mean intraocular pressure measured 1 hour after Nd:YAG laser posterior capsulotomy was compared between participants who received one drop of 0.5% topical timolol maleate before the procedure and participants who received standard care without prophylactic timolol.

Sponsors and collaborators

Lead sponsor

CMH Multan Institute of Medical Sciences

Other Gov

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jul 27, 2026
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.